Bright Minds Biosciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRUG research report →
Companybrightmindsbio.com
Bright Minds Biosciences Inc. , a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
- CEO
- Ian McDonald
- IPO
- 2021
- Employees
- 26
- HQ
- New York City, BC, CA
Price Chart
Valuation
- Market Cap
- $642.50M
- P/E
- -43.75
- P/S
- 0.00
- P/B
- 9.73
- EV/EBITDA
- -40.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -28.46%
- ROIC
- -21.50%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,229,348 · -336.46%
- EPS
- $-1.78 · -173.85%
- Op Income
- $-13,937,584
- FCF YoY
- -369.77%
Performance & Tape
- 52W High
- $123.75
- 52W Low
- $23.18
- 50D MA
- $80.69
- 200D MA
- $69.41
- Beta
- -0.19
- Avg Volume
- 168.45K
Get TickerSpark's AI analysis on DRUG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Cormorant Asset Management, LP | sell | 109,331 |
| Nov 4, 24 | Cormorant Asset Management, LP | buy | 184,331 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 3,107 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 7,150 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 39,743 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 4,609 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 19,169 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,700 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,600 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 8,900 |
Our DRUG Coverage
We haven't published any research on DRUG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DRUG Report →